TrialFuture oncology (London, England)2017

A randomized Phase II study of veliparib with temozolomide or carboplatin/paclitaxel versus placebo with carboplatin/paclitaxel in BRCA1/2 metastatic breast cancer: design and rationale.

Steven J Isakoff et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.